-
公开(公告)号：US08377689B2
公开(公告)日：2013-02-19
申请号：US12890319
申请日：2010-09-24
Applicant: Wen-Ghih Tsang , Yanping Wang , Jinghua Tang
Inventor： Wen-Ghih Tsang , Yanping Wang , Jinghua Tang
CPC classification number: C12N5/0676 , C12N2501/117 , C12N2501/12 , C12N2533/54
Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.
Abstract translation: 本发明涉及选择性细胞表面标志物的发现，其允许选择具有高分化为胰岛素产生细胞或产生胰岛素的细胞聚集体的高倾向的胰腺干细胞的唯一子集。
-
公开(公告)号：US07807459B2
公开(公告)日：2010-10-05
申请号：US11237094
申请日：2005-09-27
Applicant: Wen-Ghih Tsang , Yanping Wang , Jinghua Tang
Inventor： Wen-Ghih Tsang , Yanping Wang , Jinghua Tang
CPC classification number: C12N5/0676 , C12N2501/117 , C12N2501/12 , C12N2533/54
Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.
Abstract translation: 本发明涉及选择性细胞表面标志物的发现，其允许选择具有高分化为胰岛素产生细胞或产生胰岛素的细胞聚集体的高倾向的胰腺干细胞的唯一子集。
-
公开(公告)号：US20070072292A1
公开(公告)日：2007-03-29
申请号：US11237094
申请日：2005-09-27
Applicant: Wen-Ghih Tsang , Yanping Wang , Jinghua Tang
Inventor： Wen-Ghih Tsang , Yanping Wang , Jinghua Tang
CPC classification number: C12N5/0676 , C12N2501/117 , C12N2501/12 , C12N2533/54
Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.
Abstract translation: 本发明涉及选择性细胞表面标志物的发现，其允许选择具有高分化为胰岛素产生细胞或产生胰岛素的细胞聚集体的高倾向的胰腺干细胞的唯一子集。
-
4.发明申请Methods of Selecting Pancreatic Endocrine Cells Using Protein Synthesis Inhibitors 审中-公开使用蛋白质合成抑制剂选择胰腺内分泌细胞的方法公开(公告)号：US20070015279A1
公开(公告)日：2007-01-18
申请号：US11419093
申请日：2006-05-18
Applicant: Wen-Ghih Tsang , Hong-Jung Chen , Yiping Tu , Yanping Wang
Inventor： Wen-Ghih Tsang , Hong-Jung Chen , Yiping Tu , Yanping Wang
CPC classification number: C12N5/0677 , A61K35/12
Abstract: The present invention relates to methods of selecting pancreatic endocrine cells from total pancreatic cells by incubation with protein synthesis inhibitors.
Abstract translation: 本发明涉及通过与蛋白质合成抑制剂一起温育从胰腺胰腺细胞中选择胰腺内分泌细胞的方法。
-
公开(公告)号：US07101546B2
公开(公告)日：2006-09-05
申请号：US10326190
申请日：2002-12-20
Applicant: Wen-Ghih Tsang , Tianli Zheng , Yanping Wang
Inventor： Wen-Ghih Tsang , Tianli Zheng , Yanping Wang
CPC classification number: A61L27/3804 , A61K9/1652 , A61K35/12 , A61L27/3834 , A61L27/3895 , C12N5/0676 , C12N5/0677
Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.
-
Patent Agency Ranking
公开(公告)号：US20130053304A1
公开(公告)日：2013-02-28
申请号：US13643840
申请日：2011-04-29
Applicant: Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
Inventor： Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
IPC: A61K38/26 , A61P3/10 , A61P3/08 , A61P3/04 , A61P9/12 , A61P1/04 , A61P25/00 , A61P9/10 , A61P9/00 , A61P7/02 , A61P1/00 , C07K14/605 , A61P3/06
CPC classification number: C07K14/605 , A61K38/00
Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.
Abstract translation: 本发明提供如下式所示的胰高血糖素样肽-1（GLP-1）类似物，其中X选自甘氨酸和甘氨酰胺。 GLP-1类似物相对于序列GLP-1具有位置8的非蛋白原性氨基酸残基，并且用包含两个酸性基团的部分酰化至位置26的赖氨酸残基。GLP-1类似物对 二肽基肽酶IV，以使体内延长半衰期。 还提供了GLP-1类似物在征服血糖中的用途。
-
7.发明申请Cell Locking Method for Mobile Terminal and Mobile Terminal Capable of Locking Cell 有权用于移动终端的小区锁定方法和能够锁定小区的移动终端公开(公告)号：US20120202463A1
公开(公告)日：2012-08-09
申请号：US13501299
申请日：2010-08-25
Applicant: Yanping Wang , Yanqiang Zuo , Hu Feng
Inventor： Yanping Wang , Yanqiang Zuo , Hu Feng
IPC: H04W12/08
CPC classification number: H04W48/20
Abstract: A cell locking method for a mobile terminal and a mobile terminal capable of locking a cell are disclosed in the present invention. The method includes: the mobile terminal acquiring a system identification (SID), a network identification (NID), a base station identifier (BASE ID) and a pseudo-random number (PN) of a current cell; judging whether the SID, NID, BASE ID and PN are already stored in a database of the mobile terminal, if yes, then setting the mobile terminal to a normal status; judging whether the SID, the NID, and the PN are already stored in the database of the mobile terminal and the database is not full, or whether the BASE ID and PN are already stored in the database of the mobile terminal, if yes, then transferring to D; and D. writing the SID, NID, BASE ID and PN into the database of the mobile terminal.
Abstract translation: 在本发明中公开了一种用于移动终端和能够锁定小区的移动终端的小区锁定方法。 该方法包括：移动终端获取当前小区的系统标识（SID），网络标识（NID），基站标识符（BASE ID）和伪随机数（PN）; 判断SID，NID，BASE ID和PN是否已经存储在移动终端的数据库中，如果是，则将移动终端设置为正常状态; 判断SID，NID和PN是否已经存储在移动终端的数据库中，并且数据库未满，或者BASE ID和PN是否已经存储在移动终端的数据库中，如果是，则 转移到D; 以及D.将SID，NID，BASE ID和PN写入到移动终端的数据库中。
-
公开(公告)号：US20070193409A2
公开(公告)日：2007-08-23
申请号：US11356723
申请日：2006-02-17
Applicant: Jilin He , Luntao Pan , Aiguo Zheng , Yuewei Cheng , Yuezhong Ma , Hongdong Liu , Guoqi Yang , Chunxiang Wang , Yanping Wang , Shiping Zheng
Inventor： Jilin He , Luntao Pan , Aiguo Zheng , Yuewei Cheng , Yuezhong Ma , Hongdong Liu , Guoqi Yang , Chunxiang Wang , Yanping Wang , Shiping Zheng
IPC: B22F9/04
CPC classification number: B22F1/0096 , B22F2998/00 , B22F2998/10 , B22F2999/00 , H01G9/0525 , B22F9/22 , B22F9/023 , B22F1/0014 , B22F1/0048 , B22F1/0055 , B22F1/0085 , B22F2201/20 , B22F9/04 , B22F2009/042
Abstract: A method for spherically granulating and agglomerating metal particles such as tantalum and/or niobium powders is described in the present invention, which includes the steps of: a). comminuting the metal particles to form fine particles having D50 less than 50 μm; b). granulating the comminuted metal particles comprising volatile liquid, for example, tantalum and/or niobium particles comprising volatile liquid, to form wet spherical particles; c). still drying the wet spherical particles and removing volatile liquid to form flowable pre-agglomerated particles with increased bulk density; d). heat treating the pre-agglomerated particles; e). screening the heat treated powder to obtain the flowable agglomerated particles. The present invention provides a flowable spherical agglomerated metal particles, and especially tantalum and/or niobium particles having improved properties. The present agglomerated tantalum powder have a flow rate of at least about 2.0 g/sec, a BET surface area of from about 0.2 to about 6.0 m2/g, a FSSS of at least 1.0 μm, a Scott bulk density of from about 1.2 g/cm3 to about 5.5 g/cm3. The present agglomerated niobium powder have a flow rate of at least about 1.0 g/sec, a BET surface area of from about 0.5 to about 8.0 m2/g, a FSSS of at least 1.0 μm, a Scott bulk density of from about 0.7 g/cm3 to about 3.5 g/cm3. Said tantalum and/or niobium metal particles have improved pore size distribution of the sintered anodes and increased pellet crush strength. The present invention further provides an electrolytic capacitor anodes made from the tantalum and/or niobium particles according to the present invention having a capacitance of from about 5,000 μFV/g to about 300,000 μFV/g.
-
9.发明授权Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof 有权作为缺氧模拟物的化合物的稳定多晶形式及其用途公开(公告)号：US09238637B2
公开(公告)日：2016-01-19
申请号：US14166203
申请日：2012-07-30
Applicant: Xinshan Kang , Wei Long , Fei Wang , Cunbo Ma , Liufeng Zhou , Yunyan Hu , Yanping Wang , Hong Cao , Yinxiang Wang , Fenlai Tan
Inventor： Xinshan Kang , Wei Long , Fei Wang , Cunbo Ma , Liufeng Zhou , Yunyan Hu , Yanping Wang , Hong Cao , Yinxiang Wang , Fenlai Tan
IPC: A01N43/16 , C07D311/56
CPC classification number: C07D311/56
Abstract: The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed.
Abstract translation: 公开了式I化合物的多晶型物，其制备方法，包括制备中间体，其药物组合物，以及上述多晶型物在制备用于治疗疾病，病症或病症的药物中的用途。
-
公开(公告)号：US20130225587A1
公开(公告)日：2013-08-29
申请号：US13884470
申请日：2011-11-09
Applicant: Xinshan Kang , Wei Long , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Yunyan Hu , Fenlai Tan , Yinxiang Wang
Inventor： Xinshan Kang , Wei Long , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Yunyan Hu , Fenlai Tan , Yinxiang Wang
IPC: C07D417/14 , C07D405/14 , C07D233/88 , C07D417/12 , C07D241/20 , C07D285/08 , C07D401/14 , C07D405/12
CPC classification number: C07D417/14 , C07D213/74 , C07D213/80 , C07D213/803 , C07D233/88 , C07D241/20 , C07D277/42 , C07D285/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D417/12
Abstract: The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders.
Abstract translation: 提供式（I）的化合物，其药学上可接受的盐，其溶剂化物，其螯合物，其非共价络合物或上述化合物的产物或上述任何形式的混合物。 化合物在制备用于治疗和/或预防糖尿病，肥胖症和相关疾病的药物中的用途。
-
-
-
-
-
-
-
-
-
Search Results
35
records
(took 0.016 seconds)
